Roche halts lung drug combo test

Share this article:

Roche has canned its exploratory combination of onartuzumab and Tarceva among previously treated, advanced non-small cell lung cancer patients with MET-positive tumors.

The company said in a statement Monday that it halted Phase-III studies “due to a lack of clinically meaningful efficacy.”

The company also said the findings have prompted a review of its other onartuzumab clinical trials.

Monday's news follows a Reuters story that indicates that although Roche and Novartis have been buddying up of late that a merger is not in the works.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions